CSCI — COSCIENS Biopharma Share News
0.000.00%
Last trade - 00:00- CA$9.55m
- CA$4.91m
- $7.50m
Brief: Aeterna Zentaris Granted 180-Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Rule
Brief: Aeterna Zentaris Announces European Licensing Agreement With Consilient Health Ltd For Commercialization Of Macimorelin
Brief: Aeterna Zentaris Amends License Agreement With Novo Nordisk For Commercialization And Development Of Macimorelin
Brief: Aeterna Zentaris Reports Qtrly Net Loss Of $1.1 Million, Or $0.02 Loss Per Common Share
Brief: Aeterna Says Recently Secured Funding Bolsters Cash Runway To Fund Operations
Brief: Aeterna Zentaris Files Prospectus Related To Disposition Of Up To 10.2 Mln Common Shares
Brief: Aeterna Zentaris Announces $7.0 Mln Registered Direct Offering Priced At-The-Market
Brief: Aeterna Zentaris Announces Continued Expansion Of Intellectual Property Portfolio For Macimorelin
Brief: Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance No Immediate Impact On Listing
Brief: Lind Global Macro Fund Reports 9.9% Passive Stake In Aeterna Zentaris Inc As Of July 2
Brief: Aeterna Zentaris Announces Pricing Of $12 Million Public Offering
Brief: Aeterna Files For Offering Of Up To 14.5 Million Units, 14.5 Million Pre-Funded Units
Brief: Aeterna Zentaris Announces Distribution Agreement With Megapharm
Brief: Aeterna Zentaris Files Prospectus Related To Disposition Of Up To 6.2 Mln Common Shares - SEC Filing
Brief: Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Aeterna Zentaris Receives Extension From Nasdaq To Satisfy Continuing Listing Requirements
Brief: Aeterna Zentaris Reports First Quarter 2020 Financial And Operating Results
Brief: Aeterna Zentaris Receives Nasdaq Notice Of Non-Compliance
Brief: Aeterna Zentaris Announces EMA Decision To Accept Modification To Agreed Pediatric Investigation Plan For Macimorelin